About 10% of the U.S. population fits into the highest-risk category, with a 20% or higher risk of a cardiac event; 54% are ...

The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...

Analysis of the FOURIER trial shows that evolocumab provides greater MACE risk reduction in patients with higher BMI and stable ASCVD.

Atherosclerotic cardiovascular disease is linked to plaque buildup in blood vessels. It can increase the risk of serious cardiovascular events, such heart attack and stroke. Statins are a medication ...

Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of ...

NEW YORK — New insights into colchicine's disruption of the pathway that contributes to arterial inflammation and new clinical studies of the drug could pave the way toward greater use of the ...

HANGZHOU, China--(BUSINESS WIRE)--Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA approval of ...

“High-sensitivity CRP has been shown to be an independent marker of risk in addition to and in some cases over and above all ...